| Website | viamet.com |
| Category | BioTech |
| Phone | 919-467-8539 |
| Employees | |
| Description | Drug Developer |
| TOTAL | $22M |
| FUNDING TOTAL | $22M |
| Series A, 6/07 Hatteras Venture Partners InterSouth Partners | $4M |
| Series B, 7/09 Novartis Option Fund Lilly Ventures InterSouth Partners Hatteras Venture Partners Lurie Investment Fund Astellas Venture Management | $18M |
Viamet Pharmaceuticals discovers and develops “best-in-class” inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet’s disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet’s best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
